• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SIGA Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/12/25 4:18:33 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SIGA alert in real time by email
    false12-310001010086NASDAQ00010100862025-06-102025-06-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15 (d) OF
    THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 10, 2025

    SIGA TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

    Delaware
    0-23047
    13-3864870
    (State or other jurisdiction of incorporation or organization)
    (Commission file number)
    (I.R.S. employer identification no.)

    31 East 62nd Street
    New York, New York
     
    10065
    (Address of principal executive offices)
     
    (Zip code)

    Registrant’s telephone number, including area code: (212) 672-9100

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which
    registered
    common stock, $.0001 par value
    SIGA
    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


    Item 5.03.
    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On June 10, 2025, the Board of Directors (the “Board”) of SIGA Technologies, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s Amended and Restated By-laws (as so amended and restated, the “By-laws”), effective as of such date.

    The amendments provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain state corporate law or shareholder derivative claims, and that the federal district courts of the United States are the exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.

    The foregoing summary of the By-laws is qualified in its entirety by reference to the By-laws filed as Exhibit 3.1 hereto and incorporated herein by reference.

    Item 5.07.
    Submission of Matters to a Vote of Security Holders.

    At the 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) of the Company held on June 10, 2025, stockholders representing 64,026,721 shares of common stock, or 89.62% of the shares of common stock outstanding as of the April 17, 2025 record date, attended or were represented by proxy. The items listed below were submitted to a vote of the stockholders who attended or were represented by proxy, and were entitled to vote at, the 2025 Annual Meeting. Final voting results are shown below.

    At the 2025 Annual Meeting, the stockholders of the Company (i) elected eight director nominees to hold office until the 2026 Annual Meeting of Stockholders of the Company and their successors are elected and qualified and until their earlier resignation or removal, (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, and (iii) approved the amendment to the Amended and Restated Certificate of Incorporation to limit the liability of officers in certain circumstances. Set forth below are the final voting results for the three proposals submitted to a vote of the stockholders.

    (1) Election of the following individuals to hold office as directors of the Company for terms of one year.

    Number of Shares Voted

    Name
    For
    Withheld
         
    Jaymie A. Durnan
    48,379,614
    4,610,051
         
    Harold E. Ford, Jr
    52,059,595
    930,070
         
    General John M. Keane
    52,112,772
    876,893
         
    Joseph W. Marshall, III
    47,752,003
    5,237,662
         
    Gary J. Nabel, M.D., Ph.D.
    51,813,611
    1,176,054
         
    Julian Nemirovsky
    52,020,615
    969,050
         
    Diem Nguyen, Ph.D., MBA
    51,839,842
    1,149,823
         
    Holly L. Phillips, M.D.
    51,508,807
    1,480,858

    With respect to each director nominee there were 11,037,056 broker “non votes.”


    (2) Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.

    Number of Shares Voted

    For
    Against
    Abstain
    62,443,679
    1,560,255
    22,787



    (3) Approval of amendment to the Amended and Restated Certificate of Incorporation to limit the liability of officers in certain circumstances.

    Number of Shares Voted

    For
    Against
    Abstain
    48,719,832
    4,251,294
    18,539

    Item 9.01.
    Financial Statements and Exhibits.

    (d)
    The following exhibits are included in this report:

    Exhibit
    No.
     
    Description
       
    3.1
     
    Amended and Restated By-laws of SIGA Technologies, Inc.
       
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    SIGA TECHNOLOGIES, INC.
       
     
    By:
    /s/ Daniel J. Luckshire
     
    Name: Daniel J. Luckshire
     
    Title: Chief Financial Officer
       
    Date: June 12, 2025
     



    Get the next $SIGA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SIGA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SIGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30Corporate Update Conference Call Today at 4:30 PM ET SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2025. "In the second quarter, we achieved two positive milestones: significant product revenues and expanded development funding under the BARDA 19C contract," stated Diem Nguyen, Chief Executive Officer. "Specifically, in the second qu

    8/5/25 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

    NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-173

    7/29/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Reports Financial Results for Three Months Ended March 31, 2025

    Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. "SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives," stated Diem Nguyen, Chief Executive Officer. "In the first quarter, an international sale of approximately $6 million marks what we expe

    5/8/25 4:05:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    SEC Filings

    View All

    SEC Form 10-Q filed by SIGA Technologies Inc.

    10-Q - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    8/5/25 4:53:57 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    8/5/25 4:06:53 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    6/12/25 4:18:33 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive VP & CFO Luckshire Daniel J converted options into 24,193 shares and covered exercise/tax liability with 12,346 shares, increasing direct ownership by 5% to 275,064 units (SEC Form 4)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    7/2/25 9:03:24 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Scientific Officer Hruby Dennis E converted options into 32,258 shares and covered exercise/tax liability with 10,467 shares, increasing direct ownership by 13% to 191,047 units (SEC Form 4)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    7/2/25 8:58:34 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Keane John M

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    6/11/25 4:34:21 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Leadership Updates

    Live Leadership Updates

    View All

    SIGA Appoints Retired General John M. Keane to its Board of Directors

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John "Jack" Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003. He is a foreign policy and national security expert who serves as an advisor to presidents, cabinet officials, members of congress, international leaders, CEOs, and business leaders. He also provide

    3/18/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Names Larry Miller General Counsel

    NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. "With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA's continued success and growth strategies forward," said Diem Nguyen, Chief Executive Officer.  "Larry will be instrumental in helping us expand our reach on a global scale and maximize the ben

    3/25/24 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

    NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company's Board of Directors. SIGA's current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. "The appointment of Diem Nguyen as our new CEO marks a significant milestone for SIGA as we continue to expand our partnerships with governments across the world in global health security initiatives and medical countermeasure preparedness," said Josep

    1/22/24 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Financials

    Live finance-specific insights

    View All

    SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30Corporate Update Conference Call Today at 4:30 PM ET SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2025. "In the second quarter, we achieved two positive milestones: significant product revenues and expanded development funding under the BARDA 19C contract," stated Diem Nguyen, Chief Executive Officer. "Specifically, in the second qu

    8/5/25 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

    NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-173

    7/29/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Reports Financial Results for Three Months Ended March 31, 2025

    Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. "SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives," stated Diem Nguyen, Chief Executive Officer. "In the first quarter, an international sale of approximately $6 million marks what we expe

    5/8/25 4:05:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SIGA Technologies Inc.

    SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    2/1/24 3:54:12 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by SIGA Technologies Inc. (Amendment)

    SC 13G/A - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    2/14/23 4:42:47 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SIGA Technologies Inc.

    SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    6/24/22 4:05:38 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care